DOI QR코드

DOI QR Code

Targeting SHCBP1 Inhibits Cell Proliferation in Human Hepatocellular Carcinoma Cells

  • Tao, Han-Chuan (Department of Hepatobiliary Surgery, Wuxi Municipal People's Hospital of Nanjing Medical University) ;
  • Wang, Hai-Xiao (Department of General Surgery, Huai'an First People's Hospital of Nanjing Medical University) ;
  • Dai, Min (Department of Hepatobiliary Surgery, Wuxi Municipal People's Hospital of Nanjing Medical University) ;
  • Gu, Cheng-Yu (Department of Hepatobiliary Surgery, Wuxi Municipal People's Hospital of Nanjing Medical University) ;
  • Wang, Qun (Chinese National Human Genome Center, Rui-Jin Hospital, Shanghai Jiaotong University School of Medicine) ;
  • Han, Ze-Guang (Chinese National Human Genome Center, Rui-Jin Hospital, Shanghai Jiaotong University School of Medicine) ;
  • Cai, Bing (Department of Hepatobiliary Surgery, Wuxi Municipal People's Hospital of Nanjing Medical University)
  • Published : 2013.10.30

Abstract

Src homology 2 domain containing (SHC) is a proto-oncogene which mediates cell proliferation and carcinogenesis in human carcinomas. Here, the SHC SH2-domain binding protein 1 (SHCBP1) was first established to be up-regulated in human hepatocellular carcinoma (HCC) tissues by array-base comparative genome hybridization (aCGH). Meanwhile, we examine and verify it by quantitative real-time PCR and western blot. Our current data show that SHCBP1 was up-regulated in HCC tissues. Overexpression of SHCBP1 could significantly promote HCC cell proliferation, survival and colony formation in HCC cell lines. Furthermore, knockdown of SHCBP1 induced cell cycle delay and suppressed cell proliferation. Furthermore, SHCBP1 could regulate the expression of activate extracellular signal-regulated kinase 1/2 (ERK1/2) and cyclin D1. Together, our findings indicate that SHCBP1 may contribute to human hepatocellular carcinoma by promoting cell proliferation and may serve as a molecular target of cancer therapy.

Keywords

Hepatocellular carcinoma;SHCBP1;SHC;cell proliferation;HCC therapy

References

  1. Bosch FX, Ribes J, Diaz M, et al (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127, S5-S16. https://doi.org/10.1053/j.gastro.2004.09.011
  2. Arzumanyan A, Reis HM, Feitelson MA (2013). Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer, 13 ,123-35. https://doi.org/10.1038/nrc3449
  3. Asano E, Hasegawa H, Hyodo T, et al (2013). The Aurora B-mediated phosphorylation of SHCBP1 regulates cytokinetic furrow ingression. J Cell Sci, 126 , 3263-70. https://doi.org/10.1242/jcs.124875
  4. Belsches AP, Haskell MD, Parsons SJ (1997). Role of c-Src tyrosine kinase in EGF-induced mitogenesis. Front Biosci, 2, d501-18.
  5. Eswarakumar VP, Lax I, Schlessinger J (2005). Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev, 16, 139-49. https://doi.org/10.1016/j.cytogfr.2005.01.001
  6. Chen J, Lai F, Niswander L (2012). The ubiquitin ligase mLin41 temporally promotes neural progenitor cell maintenance through FGF signaling. Genes Dev, 26, 803-15. https://doi.org/10.1101/gad.187641.112
  7. Debnath J (2010). p66 (Shc) and Ras: controlling anoikis from the inside-out. Oncogene, 29 , 5556-8. https://doi.org/10.1038/onc.2010.347
  8. Deng Q, Wang Q, Zong WY, et al (2010). E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation. Cancer Res, 70 ,782-91. https://doi.org/10.1158/0008-5472.CAN-09-3082
  9. Hutter D, Yo Y, Chen W, et al (2000). Age-related decline in Ras/ERK mitogen-activated protein kinase cascade is linked to a reduced association between Shc and EGF receptor. J Gerontol A Biol Sci Med Sci, 55, B125-34. https://doi.org/10.1093/gerona/55.3.B125
  10. Ito M, Iwasaki M, Takeda M, et al (2013). Measles virus non-structural C protein modulates viral RNA polymerase activity by interacting with a host protein SHCBP1. J Virol, 87, 9633-42. https://doi.org/10.1128/JVI.00714-13
  11. Leahy M, Lyons A, Krause D, et al (2004). Impaired Shc, Ras, and MAPK activation but normal Akt activation in FL5.12 cells expressing an insulin-like growth factor I receptor mutated at tyrosines 1250 and 1251. J Biol Chem, 279, 18306-13. https://doi.org/10.1074/jbc.M309234200
  12. Pelicci G, Lanfrancone L, Grignani F, et al (1992). A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell, 70, 93-104. https://doi.org/10.1016/0092-8674(92)90536-L
  13. Ravichandran KS, Lorenz U, Shoelson SE, et al (1995). Interaction of Shc with Grb2 regulates the Grb2 association with mSOS. Ann N Y Acad Sci, 766, 202-3. https://doi.org/10.1111/j.1749-6632.1995.tb26663.x
  14. Sherman M (2010). Epidemiology of hepatocellular carcinoma. Oncology, 78, 7-10. https://doi.org/10.1159/000315223
  15. Sasaoka T, Kobayashi M (2000). The functional significance of Shc in insulin signaling as a substrate of the insulin receptor. Endocr J, 47, 373-81. https://doi.org/10.1507/endocrj.47.373
  16. Schafer DF, Sorrell MF (1999). Hepatocellular carcinoma. Lancet, 353, 1253-7. https://doi.org/10.1016/S0140-6736(98)09148-X
  17. Schmandt R, Liu SK, McGlade CJ (1999). Cloning and characterization of mPAL, a novel Shc SH2 domain-binding protein expressed in proliferating cells. Oncogene, 18, 1867-79. https://doi.org/10.1038/sj.onc.1202507
  18. Sweet DT, Chen Z ,Wiley DM, et al (2012). The adaptor protein Shc integrates growth factor and ECM signaling during postnatal angiogenesis. Blood, 119, 1946-55. https://doi.org/10.1182/blood-2011-10-384560
  19. Tomilov AA, Ramsey JJ, Hagopian K, et al (2011). The Shc locus regulates insulin signaling and adiposity in mammals. Aging Cell, 10, 55-65. https://doi.org/10.1111/j.1474-9726.2010.00641.x
  20. Wang H, Wu K, Sun Y, et al (2012). STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro. BMB Rep, 45, 629-34. https://doi.org/10.5483/BMBRep.2012.45.11.086
  21. Wei YJ, Hu QQ, Gu CY, et al (2012). Up-regulation of NICE-3 as a novel EDC gene could contribute to human hepatocellular carcinoma. Asian Pac J Cancer Prev, 13, 4363-8. https://doi.org/10.7314/APJCP.2012.13.9.4363
  22. Yamauchi T,Ueki K,Tobe K, et al (1998). Growth hormone-induced tyrosine phosphorylation of EGF receptor as an essential element leading to MAP kinase activation and gene expression. Endocr J, 45, S27-31. https://doi.org/10.1507/endocrj.45.Suppl_S27
  23. Zhang H, Huang CJ, Tian Y, et al (2012). Ectopic overexpression of COTE1 promotes cellular invasion of hepatocellular carcinoma. Asian Pac J Cancer Prev, 13, 5799-804. https://doi.org/10.7314/APJCP.2012.13.11.5799

Cited by

  1. Unexpected Phenotype of Mice Lacking Shcbp1, a Protein Induced during T Cell Proliferation vol.9, pp.8, 2014, https://doi.org/10.1371/journal.pone.0105576
  2. SHCBP1 promotes synovial sarcoma cell metastasis via targeting TGF-β1/Smad signaling pathway and is associated with poor prognosis vol.36, pp.1, 2017, https://doi.org/10.1186/s13046-017-0616-z